We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Shares are down 65% YTD and well below the 200-day moving average.
Acadia Healthcare Company Overview
Zacks Rank #5 (Strong Sell) stock Acadia Healthcare Company, Inc. ((ACHC - Free Report) ) is a behavioral healthcare provider. Headquartered in Franklin, TN, Acadia Healthcare owns and operates a vast network of 262 facilities across 39 states and Puerto Rico, making it one of the largest standalone behavioral health companies in the U.S. ACHC’s healthcare facilities have ~12,000 beds with 163 comprehensive treatment centers (CTCs). Among the CTCs, 21 are owned properties of Acadia Healthcare, and 142 are leased properties.
Acadia Faces Legal & Regulatory Concerns
A bombshell 2024 New York Times ((NYT - Free Report) ) article suggested that Acadia forced patients to stay in their facilities against their will to increase profits from insurance payments. The article resulted in numerous subpoenas from the U.S. Department of Justice (DOJ) and the SEC regarding its admissions, length of stay, and billing practices. As a result, Acadia has agreed to pay massive settlements to attempt to clear its legal woes, including a $17 million settlement for a Medicaid fraud scheme in West Virginia.
Image Source: Zacks Investment Research
In addition to rising legal costs, ACHC continues to face rising costs from higher wages, benefits, and supply prices. Total expenses surged 15% year over year. Meanwhile, ongoing DOJ scrutiny and heightened media attention are likely to keep these expenses elevated, pressuring margins.
ACHC Suffers from Negative EPS Growth
ACHC is facing negative growth prospects over the next few quarters. For the current quarter, Zacks Consensus Estimates suggest EPS growth will plunge 84.38% year-over-year. Meanwhile, the negative EPS growth is expected to continue into next year.
Image Source: Zacks Investment Research
Additionally, the company’s reduced 2025 guidance reflects continued financial strain. ACHC management now expects adjusted EPS between $2.35 and $2.45, down from $2.45-$2.65 previously. Adjusted EBITDA is forecast at $650–$660 million, lower than the prior $675–$700 million range. Operating cash flow guidance was lowered to $400 to $425 million. The downgrades highlight cost pressures and slower recovery momentum across operations. Management still plans capital expenditures of $505–$515 million for 2025, suggesting limited flexibility despite moderated earnings expectations. With softer guidance and rising expenses, near-term growth prospects remain constrained.
ACHC: Relative Weakness & A Broken Chart
ACHC shares are -64.53% year-to-date, dramatically underperforming the major market indices and exhibiting troubling relative weakness. Meanwhile, shares are well below their 200-day moving average. As Paul Tudor Jones warns, “Nothing good happens below the 200-day moving average.”
Image Source: TradingView
Bottom Line
Overall, Acadia Healthcare faces a difficult near-term outlook as legal and regulatory overhangs, rising cost pressures, and sharply weakening earnings momentum weigh on operations. With guidance moving lower, margins under stress, and the stock showing pronounced technical weakness, ACHC remains challenged on both fundamental and market fronts.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Bear of the Day: Acadia Healthcare (ACHC)
Key Takeaways
Acadia Healthcare Company Overview
Zacks Rank #5 (Strong Sell) stock Acadia Healthcare Company, Inc. ((ACHC - Free Report) ) is a behavioral healthcare provider. Headquartered in Franklin, TN, Acadia Healthcare owns and operates a vast network of 262 facilities across 39 states and Puerto Rico, making it one of the largest standalone behavioral health companies in the U.S. ACHC’s healthcare facilities have ~12,000 beds with 163 comprehensive treatment centers (CTCs). Among the CTCs, 21 are owned properties of Acadia Healthcare, and 142 are leased properties.
Acadia Faces Legal & Regulatory Concerns
A bombshell 2024 New York Times ((NYT - Free Report) ) article suggested that Acadia forced patients to stay in their facilities against their will to increase profits from insurance payments. The article resulted in numerous subpoenas from the U.S. Department of Justice (DOJ) and the SEC regarding its admissions, length of stay, and billing practices. As a result, Acadia has agreed to pay massive settlements to attempt to clear its legal woes, including a $17 million settlement for a Medicaid fraud scheme in West Virginia.
Image Source: Zacks Investment Research
In addition to rising legal costs, ACHC continues to face rising costs from higher wages, benefits, and supply prices. Total expenses surged 15% year over year. Meanwhile, ongoing DOJ scrutiny and heightened media attention are likely to keep these expenses elevated, pressuring margins.
ACHC Suffers from Negative EPS Growth
ACHC is facing negative growth prospects over the next few quarters. For the current quarter, Zacks Consensus Estimates suggest EPS growth will plunge 84.38% year-over-year. Meanwhile, the negative EPS growth is expected to continue into next year.
Image Source: Zacks Investment Research
Additionally, the company’s reduced 2025 guidance reflects continued financial strain. ACHC management now expects adjusted EPS between $2.35 and $2.45, down from $2.45-$2.65 previously. Adjusted EBITDA is forecast at $650–$660 million, lower than the prior $675–$700 million range. Operating cash flow guidance was lowered to $400 to $425 million. The downgrades highlight cost pressures and slower recovery momentum across operations. Management still plans capital expenditures of $505–$515 million for 2025, suggesting limited flexibility despite moderated earnings expectations. With softer guidance and rising expenses, near-term growth prospects remain constrained.
ACHC: Relative Weakness & A Broken Chart
ACHC shares are -64.53% year-to-date, dramatically underperforming the major market indices and exhibiting troubling relative weakness. Meanwhile, shares are well below their 200-day moving average. As Paul Tudor Jones warns, “Nothing good happens below the 200-day moving average.”
Image Source: TradingView
Bottom Line
Overall, Acadia Healthcare faces a difficult near-term outlook as legal and regulatory overhangs, rising cost pressures, and sharply weakening earnings momentum weigh on operations. With guidance moving lower, margins under stress, and the stock showing pronounced technical weakness, ACHC remains challenged on both fundamental and market fronts.